Health Care-Related Economic Burden of the Polycystic Ovary Syndrome during the Reproductive Life Span
The DOI matches its Crossref record; 89 of the 90 references it cites were found in a registry or an index.
Abstract
CONTEXT: The polycystic ovary syndrome (PCOS) is the most common endocrine abnormality of reproductive-aged women today, affecting approximately 6.6% of unselected reproductive-aged women (approximately 4 million women in the United States) (1990 National Institutes of Health criteria), and potentially represents a significant financial burden to our health care. OBJECTIVE: The objective of the study was to define, using current definitions and prevalence or incidence data, the minimal economic burden that PCOS in reproductive-aged women represents for the United States. DESIGN: The study design was a literature review. SETTING: The study was conducted at a tertiary care center. PATIENTS OR OTHER PARTICIPANTS: There were no patients or other participants. INTERVENTION(S): We performed a systematic review of the published medical literature to identify studies evaluating epidemiology of reproductive-age PCOS and its clinical consequences and costs. We tied general societal cost data for the different health consequences to reproductive-age PCOS costs, using prevalence data. MAIN OUTCOME MEASURE(S): The main measure in the study was total health care-related economic costs. RESULTS: We estimated the mean annual cost of the initial evaluation to be dollar 93 million (2.1% of total costs), that of hormonally treating menstrual dysfunction/abnormal uterine bleeding to be dollar 1.35 billion (31.0% of total), that of providing infertility care to be dollar 533 million (12.2% of total), that of PCOS-associated diabetes to be dollar 1.77 billion (40.5% of total), and that of treating hirsutism to be dollar 622 million (14.2% of total). CONCLUSIONS: The total cost of evaluating and providing care to reproductive-aged PCOS women in the United States is dollar 4.36 billion. Because the cost of the diagnostic evaluation accounted for a relatively minor part of the total costs (approximately 2%), more widespread and liberal screening for the disorder appears be a cost-effective strategy, leading to earlier diagnosis and intervention and possibly the amelioration and prevention of serious sequelae.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“comprehensive screening and counseling from physicians and greater public awareness can curtail morbidity and reduce the economic burden on both the patient and the healthcare system.”
From 'I'm usually being my own doctor': women's experiences of managing polycystic ovary syndrome in Canada (2023) · cites this paper as [61]
In the citing paper
“PCOS has a high healthcare-related economic burden”
From 'I'm usually being my own doctor': women's experiences of managing polycystic ovary syndrome in Canada (2023) · cites this paper as [61]
In the citing paper
“Also from a resource allocation perspective, the financial costs related to diagnosis of PCOS are only a small fraction (2%) of the total costs associated with comprehensive care for PCOS in the United States (32).”
From Delayed Diagnosis and a Lack of Information Associated With Dissatisfaction in Women With Polycystic Ovary Syndrome (2016) · cites this paper as [32]
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,712
Self-citationMen at risk: occupation and male infertility
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,387
Amenorrhea associated with bilateral polycystic ovaries
Stein, I. F., & Leventhal, M. L. (1935) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(15)30642-6 · Cited by 2,121
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Knochenhauer, E. S., Key, T. J., Kahsar-Miller, M., Waggoner, W., Boots, L. R., & Azziz, R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5090 · Cited by 1,516
Self-citationAsunción, M., Calvo, R. M., San Millán, J. L., Sancho, J., Avila, S., & Escobar-Morreale, H. F. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6682 · Cited by 1,318
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257
Androgen Excess in Women: Experience with Over 1000 Consecutive Patients
Azziz, R., Sanchez, L. A., Knochenhauer, E. S., Moran, C., Lazenby, J., Stephens, K. C., Taylor, K., & Boots, L. R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031122 · Cited by 1,132
Self-citation
Cited by
Items 201–300 of 556
Lai, W., Li, X., Zhu, H., Zhu, X., Tan, H., Feng, P., Chen, L., & Luo, C. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.104535 · Cited by 34
Neonatal outcomes in women with polycystic ovary syndrome after frozen-thawed embryo transfer
Lin, J., Guo, H., Wang, B., Chen, Q., & Zhu, Q. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.08.1435 · Cited by 30
Melson, E., Davitadze, M., Malhotra, K., PCOS SEva working group, Mousa, A., Teede, H. J., Boivin, J., Thondan, M., Tay, C. T., & Kempegowda, P. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1217468 · Cited by 34
“36 billion (43), PCOS receives less than 0.”
BackgroundGalazis, N., Afxentiou, T., Xenophontos, M., Diamanti‐Kandarakis, E., & Atiomo, W. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0718 · Cited by 31
Evaluation of Meibomian Gland Dysfunction in Polycystic Ovary Syndrome and Obesity
Başer, G., Yildiz, N., & Çalan, M. (2016) · Current Eye Research · doi:10.1080/02713683.2016.1233985 · Cited by 31
“5% and 8%.(11) According to the Rotterdam definition, two of three criteria must be met to fit the definition of PCOS: chronic anovulation, clinical or biochemical evidence, or both, of hyper-androgenism and polycystic ovaries.”
BackgroundPolycystic ovarian syndrome: A review covering phytoconstituents for its outstrip management
Joshi, M., Shankar, R., Pathak, K., & Yadav, R. (2021) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2021.100011 · Cited by 34
Adiponectin, Leptin and Ghrelin Levels in Obese Adolescent Girls with Polycystic Ovary Syndrome
GÜRBÜZ, T., Akhan, S. E., Baştu, E., Telci, A., İyibozkurt, A. C., & Topuz, S. (2012) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2012.09.002 · Cited by 29
Artificial intelligence in polycystic ovarian syndrome management: past, present, and future
Wang, J., Chen, R., Long, H., He, J., Tang, M., Su, M., Deng, R., Chen, Y., Ni, R., Zhao, S., et al. (2025) · La radiologia medica · doi:10.1007/s11547-025-02032-9 · Cited by 39
“…PCOS women accounted for a relative majority of the total costs (approximately 98%), more widespread and liberal prevention for the disorder appears to be a cost-effective strategy, leading to earlier diagnosis and intervention, possibly the amelioration, and prevention of serious sequelae [37].”
Tang, X., Sun, Z., & Gong, L. (2017) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13462 · Cited by 31
“The condition presents a substantial health and economic burden: for example, an annual cost of up to $4bn in the USA in 2004.(3) Although PCOS has been investigated for decades, the pathophysiology is complicated and remains elusive.”
BackgroundSharmeen, S., Nomani, H., Taub, E. M., Carlson, H. E., & Yao, Q. (2021) · Clinical Rheumatology · doi:10.1007/s10067-021-05850-0 · Cited by 30
“Health care for this disorder is costly and causes a considerable financial burden [6].”
BackgroundZahid, S., Khan, M. Z., Gowda, S. N., Faza, N. N., Honigberg, M. C., Vaught, A. “. J., Guan, C. S., Minhas, A., & Michos, E. D. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.025839 · Cited by 33
Managing Polycystic Ovary Syndrome: A Cognitive Behavioral Strategy
Elizabeth, M., Leslie, N. S., & Critch, E. A. (2009) · Nursing for Women s Health · doi:10.1111/j.1751-486x.2009.01439.x · Cited by 32
Mu, L., Zhao, Y., Li, R., Lai, Y.-C., & Qiao, J. (2018) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2018.08.007 · Cited by 32
Chan, J. L., Pall, M., Ezeh, U. I., Mathur, R., Pisarska, M. D., & Azziz, R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz264 · Cited by 28
Self-citationYang, Y., Yang, L., Qi, C., Hu, G., Wang, L., Sun, Z., & Ni, X. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11469 · Cited by 40
The association between fertility diet score and polycystic ovary syndrome: A Case-Control study
Noormohammadi, M., Eslamian, G., Malek, S., Shoaibinobarian, N., & Mirmohammadali, S. N. (2021) · Health Care For Women International · doi:10.1080/07399332.2021.1886298 · Cited by 31
Kiconco, S., Teede, H. J., Azziz, R., Norman, R. J., & Joham, A. E. (2021) · Seminars in Reproductive Medicine · doi:10.1055/s-0041-1735259 · Cited by 33
Self-citationArefi, S., Mottaghi, S., & Sharifi, A. M. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2013.769513 · Cited by 27
Hiam, D., Patten, R. K., Gibson‐Helm, M. E., Moreno‐Asso, A., McIlvenna, L. C., Levinger, I., Harrison, C. L., Moran, L., Joham, A. E., Parker, A. G., et al. (2019) · Trials · doi:10.1186/s13063-019-3313-8 · Cited by 29
The Societal Value of Broader Access to Antiobesity Medications
Kabiri, M., Sexton Ward, A., Ramasamy, A., van Eijndhoven, E., Ganguly, R., Smolarz, B. G., Zvenyach, T., Goldman, D. P., & Baumgardner, J. R. (2020) · Obesity · doi:10.1002/oby.22696 · Cited by 26
Olaniyi, K. S., Areloegbe, S. E. J., & Oyeleke, M. B. (2022) · Endocrine · doi:10.1007/s12020-022-03191-9 · Cited by 26
“Hence, the present observations are in consonance with the previous studies [8, 9], validating endocrine disturbance as a critical component of PCOS.”
BackgroundResultWitchel, S. F., Recabarren, S. E., González, F., Diamanti‐Kandarakis, E., Cheang, K. I., Dulęba, A. J., Legro, R. S., Homburg, R., Pasquali, R., Løbo, R. A., et al. (2012) · Endocrine · doi:10.1007/s12020-012-9701-4 · Cited by 30
“While PCOS contributes to *75 % of anovulation-related infertility [3], it also accounts for 12–28 % of overweight and obese (BMI C 25) women, 15–36 % of women with type 2 diabetes mellitus (type 2 DM) [4–7], and doubling of the lifetime risk for cardiovascular disease [8].”
BackgroundKiconco, S., Tay, C. T., Rassie, K. L., Azziz, R., Teede, H. J., & Joham, A. E. (2022) · Clinical Endocrinology · doi:10.1111/cen.14647 · Cited by 25
“Taken together, these PCOS‐related disorders lead to a diminished quality of life for women affected by the condition(13) and cause substantial and escalating health and economic burden.(11,14) The recent international evidence‐based guideline for the diagnosis and management of PCOS endorsed the 2003 Rotterdam criter…”
BackgroundSelf-citationPossible cognition changes in women with polycystic ovary syndrome: a narrative review
Naz, M. S. G., Rahnemaei, F. A., Tehrani, F. R., Sayehmiri, F., Ghasemi, V., Banaei, M., & Ozgoli, G. (2023) · Obstetrics & Gynecology Science · doi:10.5468/ogs.22165 · Cited by 28
“Disorders and complications associated with PCOS impose significant psychological and economic burdens on different people in different countries [4-7].”
BackgroundPolycystic Ovary Syndrome and Chronic Inflammation: Pharmacotherapeutic Implications
Sirmans, S. M., Weidman-Evans, E., Everton, V., & Thompson, D. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q514 · Cited by 24
Vuong, L. N., Ho, V. N. A., Ho, T. M., Dang, V. Q., Phung, T. H., Giang, N. H., Le, A. H., Pham, T. D., Wang, R., Norman, R. J., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-023413 · Cited by 26
“The proportion of subfertile women who have PCOS is about 50%.(2) Although subfertile women with PCOS usually benefit from conventional treatments, such as ovulation induction and laparoscopic ovarian drilling,(3) 4 some will ultimately need assisted reproductive techniques such as controlled ovarian hyperstimulation…”
BackgroundDefining polycystic ovary syndrome phenotype in Vietnamese women
Cao, N. T., Lê, M. T., Nguyễn, V. Q. H., Pilgrim, J., Lê, V. N. S., Le, D. D., Pham, C. K., Aharon, D. A., & Hill, M. J. (2019) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.14097 · Cited by 27
“In addition to ovulatory dysfunction, PCOS is related to metabolic disorders including obesity, glucose intolerance, dyslipidemia, hypertension, and a sevenfold increase in the risk of type 2 diabetes mellitus and cardiovascular disease.(2) In the United States, over 4.”
BackgroundInfluentialDon’t Trust Your Gut: When Gut Microbiota Disrupt Fertility
Silva, M. S. B., & Giacobini, P. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.005 · Cited by 25
Hatanaka, Y., Wada, K., & Kabuta, T. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.04.008 · Cited by 25
Chen, W., Miao, J., Chen, J., & Chen, J. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-024-01583-1 · Cited by 24
How polycystic ovary syndrome came into its own
Azziz, R. (2021) · F&S Science · doi:10.1016/j.xfss.2020.12.007 · Cited by 34
Self-citationCrespo, R. P., da Rocha, T. J. C. M., Montenegro, L. R., Nishi, M. Y., Jorge, A. A. L., Maciel, G. A. R., Baracat, E. C., Latronico, A. C., Mendonca, B. B., & Gomes, L. G. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac106 · Cited by 25
“It is characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovary morphology (1-3).”
BackgroundInfluentialKiconco, S., Mousa, A., Azziz, R., Enticott, J., Сутурина, Л. В., Zhao, X., Gambineri, A., Tehrani, F. R., Yıldız, B. O., Kim, J., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11111953 · Cited by 28
“Women with PCOS are at an increased risk of adverse reproductive, metabolic, psychological, oncological, pregnancy, and long-term offspring metabolic and developmental disorders, which impair their quality of life [2,3] in addition to straining health and economic resources [4].”
BackgroundSelf-citationTreatment pathways traversed by polycystic ovary syndrome (PCOS) patients: A mixed-method study
Kaur, I., Suri, V., Rana, S. V., & Singh, A. (2021) · PLOS ONE · doi:10.1371/journal.pone.0255830 · Cited by 23
Dysbiotic alteration in the fecal microbiota of patients with polycystic ovary syndrome
Chen, K., Geng, H., Ye, C., & Liu, J. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.04291-23 · Cited by 27
“According to the Food and Drug Administration (FDA), the cost of managing and treating PCOS in the United States exceeded $4 billion in 2004, not including the cost of managing and treating the long-term complications of PCOS (9).”
BackgroundIntergenerational Associations of Chronic Disease and Polycystic Ovary Syndrome
Davies, M. J., Marino, J. L., Willson, K. J., March, W. A., & Moore, V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025947 · Cited by 26
Prodoehl, M. J., Irving‐Rodgers, H. F., Bonner, W. M., Sullivan, T. M., Micke, G. C., Gibson, M. A., Perry, V. E. A., & Rodgers, R. J. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.03.002 · Cited by 23
Jason, J. M. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.288 · Cited by 24
Shen, W., Zhang, Y., Li, W., Cong, J., Zhou, Y., Ng, E. H. Y., & Wu, X. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003646 · Cited by 23
Tay, C. T., Joham, A. E., Hiam, D., Gadalla, M. A., Pundir, J., Thangaratinam, S., Teede, H. J., & Moran, L. (2018) · Clinical Endocrinology · doi:10.1111/cen.13753 · Cited by 25
Survey analysis of quantitative and qualitative menstrual cycle tracking technologies
Stujenske, T. M., Mu, Q., Pérez Capotosto, M., & Bouchard, T. P. (2023) · Medicina · doi:10.3390/medicina59091509 · Cited by 22
“The only standalone technology validated for avoiding pregnancy is Natural Cycles [25], although the Marquette Method of Natural Family Planning, which incorporates multiple technologies, has also been validated for avoiding pregnancy [16,25].”
BackgroundSharma, A., Sarwal, Y., Devi, N. K., & Saraswathy, K. N. (2025) · Reproductive Health · doi:10.1186/s12978-025-02019-9 · Cited by 32
“This high frequency of PCOS, as well as its link with ovulation and menstruation abnormalities, infertility, hair loss, and metabolic issues, cause significant financial burden on the nation [2, 20].”
Sümbül, H. E., Avci, B. S., Bankir, M., Pekoz, B. C., Gülümsek, E., & Koç, A. S. (2022) · Ultrasound Quarterly · doi:10.1097/ruq.0000000000000592 · Cited by 23
Polycystic Ovary Syndrome and the Neuroendocrine Consequences of Androgen Excess
Silva, M. S. B., & Campbell, R. E. (2022) · Comprehensive physiology · doi:10.1002/cphy.c210025 · Cited by 27
Killer-cell immunoglobulin-like receptors associated with polycystic ovary syndrome
Elpídio, L. N. S., de Alencar, J. B., Tsuneto, P. Y., Alves, H. V., Toretta, M. T., Taura, S. K. I., Visentainer, J. E. L., & Sell, A. M. (2018) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2018.08.003 · Cited by 23
Zhao, J., Sui, X., Shi, Q., Su, D., & Lin, Z. (2022) · Medicine · doi:10.1097/md.0000000000030006 · Cited by 25
“[1–3] In addition to infertility and abnormal menstruation,[4–6] patients also face economic burdens and long-term health risks.[7,8] Numerous studies have demonstrated that PCOS patients tend to have insulin resistance.”
BackgroundHussein, B., & Alalaf, S. (2013) · Open Journal of Obstetrics and Gynecology · doi:10.4236/ojog.2013.37104 · Cited by 29
“[22] reported an incidence of 12% - 14% [22], while Belosi et al.”
BackgroundDificuldades e armadilhas no diagnóstico da síndrome dos ovários policísticos
Marcondes, J. A. M., Barcellos, C. R. G., & Rocha, M. P. (2011) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302011000100002 · Cited by 42
“Se até a década de 80 do século passado a SOP era considerada uma desordem com consequências reprodutiva e estética, com risco aumentado para carcinoma de endométrio, a partir dessa década várias evidências demonstraram também um risco também aumentado para diabetes tipo 2, dislipidemia, hipertensão arterial e possive…”
BackgroundSóter, M. O., Ferreira, C. N., Sales, M. F., Cândido, A. L., dos Reis, F. M., Milagres, K. S., Ronda, C. R. S. C., Silva, I. D. F. O., Sousa, M. O., & Gomes, K. B. (2015) · Cytokine · doi:10.1016/j.cyto.2015.06.008 · Cited by 23
Phimphasone-Brady, P., Palmer, B., Vela, A., Johnson, R. L., Harnke, B., Hoffecker, L., Coons, H. L., & Epperson, C. N. (2022) · F&S Reviews · doi:10.1016/j.xfnr.2021.11.004 · Cited by 20
Economic Burden of Endometrial Cancer Associated With Polycystic Ovary Syndrome
Pace, L. A., Markovic, D., Buyalos, R. P., Bril, F., & Azziz, R. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae527 · Cited by 22
Self-citationPalomba, S., Seminara, G., Costanzi, F., Caserta, D., & Aversa, A. (2024) · Biomedicines · doi:10.3390/biomedicines12122859 · Cited by 21
Kujanpää, L., Arffman, R. K., Vaaramo, E., Rossi, H., Laitinen, J. H., Morin-Papunen, L. C., Tapanainen, J. S., Ala‐Mursula, L., & Piltonen, T. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0027 · Cited by 20
Berni, T. R., Morgan, C. L., & Rees, A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae518 · Cited by 25
“Azziz et al estimated the mean annual cost of the diagnostic evaluation of PCOS to be $93 million in 2014 US dollars (7).”
BackgroundResultInfluentialAndrisse, S., Garcia‐Reyes, Y., Pyle, L. L., Kelsey, M. M., Nadeau, K. J., & Cree‐Green, M. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab008 · Cited by 21
“386 Hirsutism (FGS scale) 6 (2,13) 6 (3,10) 8 (3,12) 0.”
Polycystic Ovary Syndrome Is a Family Affair
Azziz, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0477 · Cited by 26
“4 billion dollars (in 2004 figures) (20).”
Self-citationClinical and metabolic characteristics of Turkish adolescents with polycystic ovary syndrome
Ateş, S., Aydın, S., Özcan, P., Soyman, Z., Karasu, A. F. G., & Şevket, O. (2017) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2017.1345875 · Cited by 24
“LH and insulin synergically result in increasing serum levels of androgens by stimulation of the androgen secretion from the ovary and reduction in serum SHBG as well (Dunaif 1997; Azziz et al. 2005).”
BackgroundEl Maghraby, H. A., Nafee, T., Guiziry, D., & Elnashar, A. (2015) · Middle East Fertility Society Journal · doi:10.1016/j.mefs.2014.10.003 · Cited by 19
Alkoudsi, K. T., & Basheti, I. A. (2019) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2019.08.027 · Cited by 22
Rooney, S., & Pendry, B. A. (2014) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2014.05.001 · Cited by 21
“The health economic burden of PCOS in the USA has been estimated as ranging from $ 93 million to $ 1.77 billion annually (Azziz et al. 2005).”
BackgroundInfluentialAntić, I. B., Ilic, D. S., Bjekić-Macut, J., Bogavac, T., Milutinović, D. V., Kastratović-Kotlica, B., Milic, N. M., Stanojlović, O. P., Andric, Z. G., & Μacut, D. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0775 · Cited by 21
Prevention of type 2 diabetes mellitus in polycystic ovary syndrome: A review
Anwar, S., & Shikalgar, N. (2017) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2017.07.015 · Cited by 20
Rodriguez, E. M., Thomas, D., Druet, A., Vlajic-Wheeler, M., Lane, K. J., & Mahalingaiah, S. (2020) · JMIR Formative Research · doi:10.2196/15094 · Cited by 18
“The calculated expenses of PCOS are likely an underestimate of the actual cost of providing care because many women will live beyond reproductive age with expensive metabolic disorders such as metabolic syndrome, which adds at least US $2000 more of health care expenses annually [4,5].”
BackgroundPalomba, S., Seminara, G., Tomei, F., Marino, A. A., Morgante, G., Baldini, D., Papaleo, E., Ragusa, G., Aversa, A., Allegra, A., et al. (2025) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-025-01372-5 · Cited by 20
“In fact, PCOS is a condition with a considerable economic impact, in relation to the therapies needed to promote fertility in these patients [19].”
Increased Adrenal Androgens in Overweight Peripubertal Girls
Solorzano, C. M. B., Helm, K. D., Patrie, J. T., Shayya, R. F., Cook‐Andersen, H., Chang, R. J., McCartney, C. R., & Marshall, J. C. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00013 · Cited by 18
Ganie, M. A., Chowdhury, S., Suri, V., Joshi, B. N., Bhattacharya, P. K., Agrawal, S., Malhotra, N., Sahay, R. K., Rozati, R., Jabbar, P. K., et al. (2021) · JMIR Research Protocols · doi:10.2196/23437 · Cited by 21
Pirotta, S., Joham, A. E., Moran, L., Skouteris, H., & Lim, S. S. (2021) · Nutrition & Dietetics · doi:10.1111/1747-0080.12670 · Cited by 22
Diané, A., Pierce, W. D., Kelly, S. E., Sokolik, S., Borthwick, F., Jácome-Sosa, M., Mangat, R., Pradillo, J. M., Allan, S. M., Ruth, M. R., et al. (2016) · Frontiers in Nutrition · doi:10.3389/fnut.2016.00044 · Cited by 19
“Model of PCOS Polycystic ovary syndrome (PCOS) has become an increasing public health concern given its association with menstrual dysfunction, infertility, MetS, T2D, and CVD risk (95, 96).”
BackgroundWatanabe, Y., Fisher, L. C., Campbell, R. E., & Jasoni, C. L. (2023) · Journal of Neuroendocrinology · doi:10.1111/jne.13302 · Cited by 19
Chen, X., Hong, L., Diao, L., Yin, T., & Liu, S. (2024) · American Journal of Reproductive Immunology · doi:10.1111/aji.13854 · Cited by 17
Rossetti, R., Strinati, V., Caputi, A., Risi, R., Spizzichini, M. L., Mondo, A., Spiniello, L., Lubrano, C., Giancotti, A., Tuccinardi, D., et al. (2024) · Metabolites · doi:10.3390/metabo14120691 · Cited by 19
Azelaic Acid in the Treatment of Acne in Adult Females: Case Reports
Vargas‐Diez, E., Hofmann, M. A., Bravo, B. S. F., Malgazhdarova, G., Алиевна, К. О., & Yutskovskaya, Y. A. (2013) · Skin Pharmacology and Physiology · doi:10.1159/000354889 · Cited by 17
Insulin-sensitizing agents and reproductive function in polycystic ovary syndrome patients
Palomba, S., Falbo, A. I., Orio, F., & Zullo, F. (2008) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e328307ebc5 · Cited by 18
Bushell, A., & Crespi, B. J. (2024) · Frontiers in Reproductive Health · doi:10.3389/frph.2024.1475132 · Cited by 20
“PCOS is commonly associated with high BMI and insulin resistance (117 – 119), which appears to be due, in part, to the modern obesogenic environment characterized by low physical activity and high-energy food intake (9).”
BackgroundSong, J., Xiang, S., Yang, Y., & Sun, Z. (2019) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2019.100944 · Cited by 16
Jin, L., Yu, J., Chen, Y., Pang, H., Sheng, J., & Huang, H. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.689897 · Cited by 17
Yasmin, A., Roychoudhury, S., Sengupta, P., Ahmed, A. B. F., Madhu, N. R., Choudhury, A. P., Kolesárová, A., Dutta, S., & Rosas, I. M. (2025) · Therapeutic Advances in Reproductive Health · doi:10.1177/26334941251384195 · Cited by 17
The effect of hydrogen-rich water on letrozole-induced polycystic ovary syndrome in rats
Makav, M., Kuru, M., Aras, Ş. Y., SARI, E. K., Bulut, M., & Alwazeer, D. (2023) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2023.103332 · Cited by 15
Huddleston, H. G., Milani, A. R., & Blank, R. (2024) · F&S Reports · doi:10.1016/j.xfre.2024.02.004 · Cited by 16
“Viewed at scale, productivity loss by a percentage of individuals with this common disorder adds to the already substantial economic burden of PCOS (14).”
BackgroundWomen with Polycystic Ovary Syndrome: A Marginalized Population in the United States
Sanchez, N. (2019) · Health & Social Work · doi:10.1093/hsw/hlz033 · Cited by 16
Self-Administered Questionnaire to Screen for Polycystic Ovarian Syndrome
Bedrick, B. S., Eskew, A. M., Chavarro, J. E., & Jungheim, E. S. (2020) · Women s Health Reports · doi:10.1089/whr.2020.0073 · Cited by 24
“However, only 2% of this cost is spent on initial evaluation.(34) Furthermore, the diagnostic process for many women with PCOS is inefficient and unsatisfactory.”
BackgroundSong, J., Park, Y., Cho, H. W., Lee, S., Kim, S., & Lim, J. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23861 · Cited by 15
Burchall, G., Linden, M. D., Teede, H. J., & Piva, T. J. (2011) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2012.01.001 · Cited by 15
Polycystic ovary syndrome and abnormalities in glucose tolerance
Bhattacharya, S. M. (2009) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2008.11.031 · Cited by 17
“A recent evaluation of the economic burden of PCOS has concluded that screening, diagnosis, and intervention prevented or ameliorated the serious complications of DM and were therefore justifiable [4].”
BackgroundSatveit, S. (2017) · Learning Health Systems · doi:10.1002/lrh2.10033 · Cited by 17
“36 billion dollars annually.(12) Currently, most healthcare providers focus on symptom management for issues such as infertility and diabetes.”
BackgroundHuang, C.-C., Yang, P.-K., Huang, Y.-S., Chen, S., Yang, Y., & Chen, M. (2023) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.12.045 · Cited by 15
Mott, M. M., Kitos, N. R., & Coviello, A. D. (2014) · Endocrine Practice · doi:10.4158/ep13414.or · Cited by 15
“Reducing rates of obesity, diabetes, and CVD in women with PCOS would help reduce the substantial chronic health burden these women face, as well as the associated financial cost to the healthcare system (37).”
BackgroundGoetsch, A. L., Kimelman, D., & Woodruff, T. K. (2017) · Springer eBooks · doi:10.1007/978-3-319-52316-3_14 · Cited by 15
Regulation of zebrafish gonadal sex differentiation
Pradhan, A., & Olsson, P. (2016) · AIMS molecular science · doi:10.3934/molsci.2016.4.567 · Cited by 14
“germ cell cancer of testis and ovary are prevalent worldwide [146].”
BackgroundCarron, R., Simon, N., Gilman-Kehrer, E., & Boyle, D. K. (2018) · The Journal of Continuing Education in Nursing · doi:10.3928/00220124-20180320-06 · Cited by 17
Mardani, N., Mozafarpoor, S., Goodarzi, A., & Nikkhah, F. (2021) · Dermatologic Therapy · doi:10.1111/dth.14915 · Cited by 14
Kumar, A., Magoffin, D. A., Munir, I., & Azziz, R. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.05.076 · Cited by 14
Self-citationMetabolic syndrome and insulin resistance in Thai women with polycystic ovary syndrome.
Pantasri, T., Vutyavanich, T., Sreshthaputra, O., Srisupundit, K., & Piromlertamorn, W. (2010) · PubMed · Cited by 17
Editorial: Polycystic ovary syndrome (PCOS): Mechanism and management
Wang, Y., Leung, P. C. K., Li, R., Wu, Y., & Huang, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1030353 · Cited by 17
“36 billion in the United States alone, even regardless of the cost of the increased risk of obstetrical and metabolic complications (2).”
BackgroundDeng, R., Wang, J., He, J., Lei, X., Zi, D., Nong, W., & Lei, X. (2023) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-023-07269-1 · Cited by 15
Shah, K. H., Kulkarni, R., Singh, R., Pannu, H. S., & Kamrai, D. (2020) · Cureus · doi:10.7759/cureus.11343 · Cited by 13
“The overall economic burden of diagnosing and treating PCOS and its related symptoms is $4.35 billion annually in the United States [7].”
BackgroundInfluentialWatanabe, Y., Prescott, M., Campbell, R. E., & Jasoni, C. L. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.13058 · Cited by 15
Air pollution exposure and pregnancy outcomes among women with polycystic ovary syndrome
Zhu, Q., Cai, J., Guo, H., Zhao, Y. M., & Lin, J. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1066899 · Cited by 13
Sankarganesh, D., Suriyakalaa, U., Ramachandran, R., Achiraman, S., Arunachalam, S., & Angayarkanni, J. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.02.009 · Cited by 13
Go Girls!—Dance-Based Fitness to Increase Enjoyment of Exercise in Girls at Risk for PCOS
King, A. K., McGill-Meeks, K., Beller, J. P., & Solorzano, C. M. B. (2019) · Children · doi:10.3390/children6090099 · Cited by 14
Metadata
- Authors
- Azziz, R., Marin, C., Hoq, L., Badamgarav, E., & Song, P.
- Affiliations
- Cedars-Sinai Medical Center (US)
- ORCID
- Azziz, Ricardo
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-08
- Volume
- 90
- Issue
- 8
- Pages
- 4650-4658
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2118575626
- Cited by
- 537
- References
- 90
- Citations by year
- 2026: 20 · 2025: 30 · 2024: 29 · 2023: 28 · 2022: 36 · 2021: 45 · 2020: 25 · 2019: 41 · 2018: 27 · 2017: 27 · 2016: 22 · 2015: 20 · 2014: 27 · 2013: 24 · 2012: 26
- FWCI
- 18.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (K24-D01346)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD029364, R01-HD29364)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- polycystic ovary syndrome, economic burden, health care costs, women of reproductive age, infertility treatment, hirsutism, abnormal uterine bleeding, menstrual disorders, PCOS screening, cost estimation
- MeSH terms
- Adolescent, Adult, Female, Humans, Polycystic Ovary Syndrome, United States, Incidence, Prevalence, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.